A citation-based method for searching scientific literature

Miriam Lobo, Sara López-Tarruella, Soledad Luque, Santiago Lizarraga, Carmen Flores-Sánchez, Oscar Bueno, Jesús Solera, Yolanda Jerez, Ricardo González Del Val, María Isabel Palomero, María Cebollero, Isabel Echavarría, Gabriela Torres, Miguel Martín, Iván Márquez-Rodas. J Genet Couns 2018
Times Cited: 3







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
Christopher P Childers, Kimberly K Childers, Melinda Maggard-Gibbons, James Macinko. J Clin Oncol 2017
130
33

Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2.
Nancie Petrucelli, Mary B Daly, Gerald L Feldman. Genet Med 2010
180
33

BRCA1/2 mutations and triple negative breast cancers.
Beth N Peshkin, Michelle L Alabek, Claudine Isaacs. Breast Dis 2010
74
33

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Soley Bayraktar, Angelica M Gutierrez-Barrera, Diane Liu, Tunc Tasbas, Ugur Akar, Jennifer K Litton, E Lin, Constance T Albarracin, Funda Meric-Bernstam, Ana M Gonzalez-Angulo,[...]. Breast Cancer Res Treat 2011
64
33

Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
Michelle W Wong-Brown, Cliff J Meldrum, Jane E Carpenter, Christine L Clarke, Steven A Narod, Anna Jakubowska, Helena Rudnicka, Jan Lubinski, Rodney J Scott. Breast Cancer Res Treat 2015
66
33

Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women.
Hayley S Thompson, Heiddis B Valdimarsdottir, Chantal Duteau-Buck, Josephine Guevarra, Dana H Bovbjerg, Cassandra Richmond-Avellaneda, David Amarel, Diana Godfrey, Karen Brown, Kenneth Offit. Cancer Epidemiol Biomarkers Prev 2002
116
33

Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer.
Kathryn J Schlich-Bakker, Herman F J ten Kroode, Carla C Wárlám-Rodenhuis, Jan van den Bout, Margreet G E M Ausems. Genet Med 2007
52
33

Multigene Testing for Hereditary Cancer: When, Why, and How.
Kenneth Offit. J Natl Compr Canc Netw 2017
5
33

Keeping pace with the times--the Genetic Information Nondiscrimination Act of 2008.
Kathy L Hudson, M K Holohan, Francis S Collins. N Engl J Med 2008
128
33

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Deann P Atchley, Constance T Albarracin, Adriana Lopez, Vicente Valero, Christopher I Amos, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi, Banu K Arun. J Clin Oncol 2008
343
33

Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics.
Kathryn J Ruddy, Betsy C Risendal, Judy E Garber, Ann H Partridge. J Clin Oncol 2016
6
33

Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
Allison W Kurian, Yun Li, Ann S Hamilton, Kevin C Ward, Sarah T Hawley, Monica Morrow, M Chandler McLeod, Reshma Jagsi, Steven J Katz. J Clin Oncol 2017
129
33

Expanding the criteria for BRCA mutation testing in breast cancer survivors.
Janice S Kwon, Angelica M Gutierrez-Barrera, Diana Young, Charlotte C Sun, Molly S Daniels, Karen H Lu, Banu Arun. J Clin Oncol 2010
99
33


Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer.
Reshma Jagsi, Kent A Griffith, Allison W Kurian, Monica Morrow, Ann S Hamilton, John J Graff, Steven J Katz, Sarah T Hawley. J Clin Oncol 2015
59
33

Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.
Anne Marie McCarthy, Mirar Bristol, Susan M Domchek, Peter W Groeneveld, Younji Kim, U Nkiru Motanya, Judy A Shea, Katrina Armstrong. J Clin Oncol 2016
73
33

American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.
Karen H Lu, Marie E Wood, Molly Daniels, Cathy Burke, James Ford, Noah D Kauff, Wendy Kohlmann, Noralane M Lindor, Therese M Mulvey, Linda Robinson,[...]. J Clin Oncol 2014
138
33

Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer .
Allison W Kurian, Kent A Griffith, Ann S Hamilton, Kevin C Ward, Monica Morrow, Steven J Katz, Reshma Jagsi. JAMA 2017
68
33

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Mary B Daly, Robert Pilarski, Michael Berry, Saundra S Buys, Meagan Farmer, Susan Friedman, Judy E Garber, Noah D Kauff, Seema Khan, Catherine Klein,[...]. J Natl Compr Canc Netw 2017
287
33

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
Ana M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, Huiqin Chen, Jennifer K Litton, Jennifer Potter, Jerry S Lanchbury, Katherine Stemke-Hale, Bryan T Hennessy, Banu K Arun,[...]. Clin Cancer Res 2011
341
33

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Priyanka Sharma, Jennifer R Klemp, Bruce F Kimler, Jonathan D Mahnken, Larry J Geier, Qamar J Khan, Manana Elia, Carol S Connor, Marilee K McGinness, Joshua M W Mammen,[...]. Breast Cancer Res Treat 2014
91
33

Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
Arup K Sinha, Jenil R Patel, Yu Shen, Naoto T Ueno, Sharon H Giordano, Debu Tripathy, David S Lopez, Carlos H Barcenas. PLoS One 2017
3
33

Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
Kenneth L Kehl, Chan Shen, Jennifer K Litton, Banu Arun, Sharon H Giordano. Breast Cancer Res Treat 2016
17
33

BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Shoshana M Rosenberg, Kathryn J Ruddy, Rulla M Tamimi, Shari Gelber, Lidia Schapira, Steven Come, Virginia F Borges, Bryce Larsen, Judy E Garber, Ann H Partridge. JAMA Oncol 2016
68
33

Two decades after BRCA: setting paradigms in personalized cancer care and prevention.
Fergus J Couch, Katherine L Nathanson, Kenneth Offit. Science 2014
199
33

Genetic/familial high-risk assessment: breast and ovarian.
Mary B Daly, Jennifer E Axilbund, Saundra Buys, Beth Crawford, Carolyn D Farrell, Susan Friedman, Judy E Garber, Salil Goorha, Stephen B Gruber, Heather Hampel,[...]. J Natl Compr Canc Netw 2010
160
33

The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.
E K Bancroft, I Locke, A Ardern-Jones, L D'Mello, K McReynolds, F Lennard, Y Barbachano, J Barwell, L Walker, G Mitchell,[...]. J Med Genet 2010
8
33


Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Pål Møller, Astrid Stormorken, Christoffer Jonsrud, Marit Muri Holmen, Anne Irene Hagen, Neal Clark, Anita Vabø, Ping Sun, Steven A Narod, Lovise Mæhle. Breast Cancer Res Treat 2013
31
33

Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Pamela J Goodwin, Kelly-Anne Phillips, Dee W West, Marguerite Ennis, John L Hopper, Esther M John, Frances P O'Malley, Roger L Milne, Irene L Andrulis, Michael L Friedlander,[...]. J Clin Oncol 2012
91
33

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes. Lancet Oncol 2015
222
33

Screening behavior in women at increased familial risk for breast cancer.
Yoland C Antill, John Reynolds, Mary Anne Young, Judy A Kirk, Katherine M Tucker, Tarli L Bogtstra, Shirley S Wong, Tracy E Dudding, Juliana L Di Iulio, Kelly-Anne Phillips. Fam Cancer 2006
33
33

Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers.
G Pichert, C Jacobs, I Jacobs, U Menon, R Manchanda, M Johnson, H Hamed, C Firth, M Evison, A Tutt,[...]. Fam Cancer 2010
11
33

Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
Mae Zakhour, Yael Danovitch, Jenny Lester, B J Rimel, Christine S Walsh, Andrew J Li, Beth Y Karlan, Ilana Cass. Gynecol Oncol 2016
41
33

Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.
Alexandra J van den Broek, Marjanka K Schmidt, Laura J van 't Veer, Rob A E M Tollenaar, Flora E van Leeuwen. PLoS One 2015
49
33

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Steven J Skates, Mark H Greene, Saundra S Buys, Phuong L Mai, Powel Brown, Marion Piedmonte, Gustavo Rodriguez, John O Schorge, Mark Sherman, Mary B Daly,[...]. Clin Cancer Res 2017
47
33

The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing.
Guan-Tian Lang, Jin-Xiu Shi, Xin Hu, Chen-Hui Zhang, Ling Shan, Chuan-Gui Song, Zhi-Gang Zhuang, A-Yong Cao, Hong Ling, Ke-Da Yu,[...]. Int J Cancer 2017
44
33

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Francisco J Candido-dos-Reis, Honglin Song, Ellen L Goode, Julie M Cunningham, Brooke L Fridley, Melissa C Larson, Kathryn Alsop, Ed Dicks, Patricia Harrington, Susan J Ramus,[...]. Clin Cancer Res 2015
90
33

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
783
33

Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.
Eveline A M Heijnsdijk, Ellen Warner, Fiona J Gilbert, Madeleine M A Tilanus-Linthorst, Gareth Evans, Petrina A Causer, Rosalind A Eeles, Reinie Kaas, Gerrit Draisma, Elizabeth A Ramsay,[...]. Cancer Epidemiol Biomarkers Prev 2012
51
33

Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Joanne Kotsopoulos, Barry Rosen, Isabel Fan, Joel Moody, John R McLaughlin, Harvey Risch, Taymaa May, Ping Sun, Steven A Narod. Gynecol Oncol 2016
51
33

Risk management options elected by women after testing positive for a BRCA mutation.
Christine Garcia, Jacqueline Wendt, Liisa Lyon, Jennifer Jones, Ramey D Littell, Mary Anne Armstrong, Tina Raine-Bennett, C Bethan Powell. Gynecol Oncol 2014
58
33

Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol.
Fahima Dossa, Maria C Cusimano, Rinku Sutradhar, Kelly Metcalfe, Tari Little, Jordan Lerner-Ellis, Andrea Eisen, Wendy S Meschino, Nancy N Baxter. BMJ Open 2018
2
50

Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Joanne Kotsopoulos, Tomasz Huzarski, Jacek Gronwald, Christian F Singer, Pal Moller, Henry T Lynch, Susan Armel, Beth Karlan, William D Foulkes, Susan L Neuhausen,[...]. J Natl Cancer Inst 2016
121
33

Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
Stephanie Kearton, Karen Wills, Michael Bunting, Penny Blomfield, Paul A James, Jo Burke. Fam Cancer 2018
4
33

Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
Sepideh Saadatmand, Inge-Marie Obdeijn, Emiel J Rutgers, Jan C Oosterwijk, Rob A Tollenaar, Gwendolyn H Woldringh, Elisabeth Bergers, Cornelis Verhoef, Eveline A Heijnsdijk, Maartje J Hooning,[...]. Int J Cancer 2015
48
33

Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
R Manchanda, A Abdelraheim, M Johnson, A N Rosenthal, E Benjamin, C Brunell, M Burnell, L Side, S Gessler, E Saridogan,[...]. BJOG 2011
72
33

Population genetic testing for cancer susceptibility: founder mutations to genomes.
William D Foulkes, Bartha Maria Knoppers, Clare Turnbull. Nat Rev Clin Oncol 2016
61
33


Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history.
Anita R Skandarajah, Susan Thomas, Kylie Shackleton, Laura Chin-Lenn, Geoffrey J Lindeman, G Bruce Mann. Breast 2017
7
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.